Overview

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

Status:
Unknown status

Trial end date:
2017-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare efficacy and safety of continuing Lamivudine plus Adefovir or Adefovir versus switching to Entecavir plus Adefovir in patients with LAM-resistant chronic hepatitis B who have suboptimal response to Lamivudine plus Adefovir or Adefovir

Phase:

Phase 4

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Adefovir
Adefovir dipivoxil
Entecavir
Lamivudine